Thermo Fisher Adds KinetiSol Technology at U.S. Drug Sites

AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, has agreed to install KinetiSol Technology equipment at Thermo Fisher’s Bend, Oregon, and Cincinnati, Ohio, oral solid drug manufacturing sites, extending KinetiSol capabilities from development and scale-up through commercial manufacturing.

As the exclusive third-party CDMO provider offering the KinetiSol Formulator technology, Thermo Fisher will provide customers with an integrated pathway to advance KinetiSol-enabled products across the drug development lifecycle.

What is KinetiSol?

KinetiSol is AustinPx’s solvent-free, fusion-based amorphous solid dispersion (ASD) technology designed to enhance the bioavailability of poorly soluble drugs while streamlining scalability and enabling more environmental and economic sustainability. The technology has been proven to open the formulation design space for challenging active pharmaceutical ingredients, including molecules with high melting points, poor organic solvent solubility, and heat sensitivity.

Since launching AustinPx in 2022, the company claims KinetiSol has been used by more than 70 pharmaceutical and biotech companies, including seven of the top ten large pharmas.

“This agreement marks an important milestone for AustinPx, our clients, and the growing number of molecules enabled by KinetiSol Technology,” said Elizabeth Hickman, CEO of AustinPx. “Thermo Fisher’s agreement with KinetiSol provides important external validation from an established global CDMO with deep experience in advanced formulation technologies and commercial manufacturing.”

“At Thermo Fisher Scientific, we are committed to helping our customers accelerate the development and delivery of life-changing medicines,” said Jennifer Cannon, President, Commercial, Biopharma Services, Thermo Fisher Scientific. “The addition of KinetiSol Technology strengthens our advanced oral drug delivery capabilities and provides customers with greater flexibility as they move innovative therapies from IND approval to commercialization.”

Related Insights

Hear in AustinPx’s own words how its KinetiSol Technology can be used for the rapid development of poorly soluble molecules targeting undruggable targets.